372 related articles for article (PubMed ID: 38474178)
1. Sindbis Virus Vaccine Platform: A Promising Oncolytic Virus-Mediated Approach for Ovarian Cancer Treatment.
Pampeno C; Opp S; Hurtado A; Meruelo D
Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474178
[TBL] [Abstract][Full Text] [Related]
2. Oncolytic virotherapy for oral squamous cell carcinoma using replication-competent viruses.
Saito K; Shirasawa H; Isegawa N; Shiiba M; Uzawa K; Tanzawa H
Oral Oncol; 2009 Dec; 45(12):1021-7. PubMed ID: 19833547
[TBL] [Abstract][Full Text] [Related]
3. IL-12 Expressing oncolytic herpes simplex virus promotes anti-tumor activity and immunologic control of metastatic ovarian cancer in mice.
Thomas ED; Meza-Perez S; Bevis KS; Randall TD; Gillespie GY; Langford C; Alvarez RD
J Ovarian Res; 2016 Oct; 9(1):70. PubMed ID: 27784340
[TBL] [Abstract][Full Text] [Related]
4. The viral approach to breast cancer immunotherapy.
Arab A; Behravan N; Razazn A; Barati N; Mosaffa F; Nicastro J; Slavcev R; Behravan J
J Cell Physiol; 2019 Feb; 234(2):1257-1267. PubMed ID: 30146692
[TBL] [Abstract][Full Text] [Related]
5. Potent and Targeted Sindbis Virus Platform for Immunotherapy of Ovarian Cancer.
Opp S; Hurtado A; Pampeno C; Lin Z; Meruelo D
Cells; 2022 Dec; 12(1):. PubMed ID: 36611875
[TBL] [Abstract][Full Text] [Related]
6. A phase 1b study of intraperitoneal oncolytic viral immunotherapy in platinum-resistant or refractory ovarian cancer.
Manyam M; Stephens AJ; Kennard JA; LeBlanc J; Ahmad S; Kendrick JE; Holloway RW
Gynecol Oncol; 2021 Dec; 163(3):481-489. PubMed ID: 34686353
[TBL] [Abstract][Full Text] [Related]
7. Preclinical and clinical trials of oncolytic vaccinia virus in cancer immunotherapy: a comprehensive review.
Li M; Zhang M; Ye Q; Liu Y; Qian W
Cancer Biol Med; 2023 Aug; 20(9):646-61. PubMed ID: 37615308
[TBL] [Abstract][Full Text] [Related]
8. Combining Vascular Normalization with an Oncolytic Virus Enhances Immunotherapy in a Preclinical Model of Advanced-Stage Ovarian Cancer.
Matuszewska K; Santry LA; van Vloten JP; AuYeung AWK; Major PP; Lawler J; Wootton SK; Bridle BW; Petrik J
Clin Cancer Res; 2019 Mar; 25(5):1624-1638. PubMed ID: 30206160
[TBL] [Abstract][Full Text] [Related]
9. Molecular and metabolic pathways mediating curative treatment of a non-Hodgkin B cell lymphoma by Sindbis viral vectors and anti-4-1BB monoclonal antibody.
Yu M; Scherwitzl I; Opp S; Tsirigos A; Meruelo D
J Immunother Cancer; 2019 Jul; 7(1):185. PubMed ID: 31307539
[TBL] [Abstract][Full Text] [Related]
10. Enhanced specific delivery and targeting of oncolytic Sindbis viral vectors by modulating vascular leakiness in tumor.
Tseng JC; Granot T; DiGiacomo V; Levin B; Meruelo D
Cancer Gene Ther; 2010 Apr; 17(4):244-55. PubMed ID: 19798121
[TBL] [Abstract][Full Text] [Related]
11. A promising future in cancer immunotherapy: Oncolytic viruses.
Seyed-Khorrami SM; Azadi A; Rastegarvand N; Habibian A; Soleimanjahi H; Łos MJ
Eur J Pharmacol; 2023 Dec; 960():176063. PubMed ID: 37797673
[TBL] [Abstract][Full Text] [Related]
12. Natural killer T cell immunotherapy combined with oncolytic vesicular stomatitis virus or reovirus treatments differentially increases survival in mouse models of ovarian and breast cancer metastasis.
Gebremeskel S; Nelson A; Walker B; Oliphant T; Lobert L; Mahoney D; Johnston B
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33722907
[TBL] [Abstract][Full Text] [Related]
13. Oncolytic Immunotherapy.
Hennessy ML; Bommareddy PK; Boland G; Kaufman HL
Surg Oncol Clin N Am; 2019 Jul; 28(3):419-430. PubMed ID: 31079797
[TBL] [Abstract][Full Text] [Related]
14. Fighting Fire With Fire: Oncolytic Virotherapy for Thoracic Malignancies.
Ekeke CN; Russell KL; Joubert K; Bartlett DL; Luketich JD; Soloff AC; Guo ZS; Lotze MT; Dhupar R
Ann Surg Oncol; 2021 May; 28(5):2715-2727. PubMed ID: 33575873
[TBL] [Abstract][Full Text] [Related]
15. Oncolytic activity of Sindbis virus in human oral squamous carcinoma cells.
Saito K; Uzawa K; Kasamatsu A; Shinozuka K; Sakuma K; Yamatoji M; Shiiba M; Shino Y; Shirasawa H; Tanzawa H
Br J Cancer; 2009 Aug; 101(4):684-90. PubMed ID: 19638980
[TBL] [Abstract][Full Text] [Related]
16. Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1.
Thomas S; Kuncheria L; Roulstone V; Kyula JN; Mansfield D; Bommareddy PK; Smith H; Kaufman HL; Harrington KJ; Coffin RS
J Immunother Cancer; 2019 Aug; 7(1):214. PubMed ID: 31399043
[TBL] [Abstract][Full Text] [Related]
17. An oncolytic virus derived from type 2 herpes simplex virus has potent therapeutic effect against metastatic ovarian cancer.
Fu X; Tao L; Zhang X
Cancer Gene Ther; 2007 May; 14(5):480-7. PubMed ID: 17290283
[TBL] [Abstract][Full Text] [Related]
18. Oncolytic virotherapy as promising immunotherapy against cancer: mechanisms of resistance to oncolytic viruses.
Goradel NH; Alizadeh A; Hosseinzadeh S; Taghipour M; Ghesmati Z; Arashkia A; Negahdari B
Future Oncol; 2022 Jan; 18(2):245-259. PubMed ID: 34821517
[TBL] [Abstract][Full Text] [Related]
19. Spatial and temporal epithelial ovarian cancer cell heterogeneity impacts Maraba virus oncolytic potential.
Tong JG; Valdes YR; Sivapragasam M; Barrett JW; Bell JC; Stojdl D; DiMattia GE; Shepherd TG
BMC Cancer; 2017 Aug; 17(1):594. PubMed ID: 28854921
[TBL] [Abstract][Full Text] [Related]
20. Oncolytic viruses as a promising therapeutic strategy for hematological malignancies.
Yang C; Hua N; Xie S; Wu Y; Zhu L; Wang S; Tong X
Biomed Pharmacother; 2021 Jul; 139():111573. PubMed ID: 33894623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
